Generated by AI
AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines. Its platform combines biology, computation, engineering, and data science to identify rare and potent antibodies from natural immune responses and advance them into drug programs. The company’s current work spans endocrinology and women’s health, immunology, oncology, and inflammation-related diseases, reflecting a broad therapeutic focus. AbCellera Biologics Inc. also develops an internal pipeline of antibody candidates and collaborates with biopharmaceutical partners on discovery and development programs. Its capabilities extend from target identification and antibody discovery through clinical manufacturing support, making it an integrated player in the antibody therapeutics market.
Website150 West 4th Ave
Vancouver, BC, V5Y 1G6
Canada
The latest articles about ABCL.
SoftBank's Q3 13F shows it exited Satellogic and cut Nu Holdings to 16.8 million shares from 17.8 million, with no new positions.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Summary of Aug 25's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Investors talking about ABCL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.